DUBs and cancer The role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors

被引:217
作者
Hussain, Sajjad [1 ]
Zhang, Ying [1 ]
Galardy, Paul J. [1 ]
机构
[1] Mayo Clin, Dept Pediat & Adolescent Med, Div Pediat Hematol Oncol, Rochester, MN 55905 USA
关键词
ubiquitin; proteasome; cancer; DUBs; oncogenes; tumor suppressor genes; signal transduction; DNA damage; mitotic checkpoint; NF-KAPPA-B; UBIQUITIN-SPECIFIC PROTEASE; BRCA1-ASSOCIATED PROTEIN-1; FAMILIAL CYLINDROMATOSIS; TERMINAL HYDROLASE-L1; TRE17; ONCOGENE; HISTONE H2B; CELL; CYLD; GENE;
D O I
10.4161/cc.8.11.8739
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
It is increasingly apparent that ubiquitin (Ub) mediated events are critical in cell proliferation. With much attention placed on the ubiquitin-proteasome pathway as a target for pharmacologic intervention, we must consider the role of deubiquitinating enzymes (DUBs) as regulators of these processes. There is a growing recognition of DUBs that are mutated in human cancers suggesting their roles as oncogenes and tumor suppressors. There is also an expanding list of enzymes that play essential roles in pathways that contribute to, or support cellular adaptations required for, malignant transformation (non-oncogenes). (Luo J, Cell 2009) Here we review the association of DUBs with cancer beginning with those with known mutations in human disease and concluding with those with a clear role in regulating cancer-relevant pathways. The molecular mechanisms underlying the association with cancer are described along with data regarding altered expression in human diseases. Although few specific, cell permeable, inhibitors exist, DUBs as a class are eminently drugable targets making it important to better understand the sites at which such modulation may have useful effects therapeutically. Given the numbers of ubiquitin-dependent pathways where we do not yet understand the role of deubiquitination, it is certain that the list of cancer-related DUBs will grow in coming years.
引用
收藏
页码:1688 / 1697
页数:10
相关论文
共 122 条
[21]   A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein [J].
Everett, RD ;
Meredith, M ;
Orr, A ;
Cross, A ;
Kathoria, M ;
Parkinson, J .
EMBO JOURNAL, 1997, 16 (07) :1519-1530
[22]   The human UNP locus at 3p21.31 encodes two tissue-selective, cytoplasmic isoforms with deubiquitinating activity that have reduced expression in small cell lung carcinoma cell lines [J].
Frederick, A ;
Rolfe, M ;
Chiu, MI .
ONCOGENE, 1998, 16 (02) :153-165
[23]   The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction [J].
Glickman, MH ;
Ciechanover, A .
PHYSIOLOGICAL REVIEWS, 2002, 82 (02) :373-428
[24]   Genomic models of metastatic cancer - Functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated polycomb group (PcG) protein chromatin silencing pathway [J].
Glinsky, GV .
CELL CYCLE, 2006, 5 (11) :1208-1216
[25]  
Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412
[26]   The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer [J].
Graner, E ;
Tang, D ;
Rossi, S ;
Baron, A ;
Migita, T ;
Weinstein, LJ ;
Lechpammer, M ;
Huesken, D ;
Zimmermann, J ;
Signoretti, S ;
Loda, M .
CANCER CELL, 2004, 5 (03) :253-261
[27]  
GRAY DA, 1995, ONCOGENE, V10, P2179
[28]   Carcinogenesis: A balance between beta-catenin and APC [J].
Gumbiner, BM .
CURRENT BIOLOGY, 1997, 7 (07) :R443-R446
[29]  
GUPTA K, 1993, ONCOGENE, V8, P2307
[30]  
GUPTA K, 1994, ONCOGENE, V9, P1729